原发性肝癌为我国高发恶性肿瘤，中医认为肝癌的主要病因是“气虚血瘀”，其治法以“益气活血”为主。黄芪-莪术为益气活血法代表性药对，已有研究表明该药对及其活性成分具有明确的抗肝癌作用。通过对黄芪-莪术药对及其活性成分抗肝癌作用机制相关文献进行梳理，从抑制细胞增殖、诱导细胞凋亡、抑制细胞迁移和侵袭、抑制新血管生成、改善免疫微环境、逆转多药耐药等角度对其抗肝癌作用机制进行综述，为黄芪-莪术药对的临床用药和抗肝癌中药新药研发提供依据。

Primary hepatocellular carcinoma is a highly prevalent malignant tumor in China. According to traditional Chinese medicine, the main cause of hepatocellular carcinoma is "qi deficiency and blood stasis", and its treatment is based on "benefitting qi and invigorating blood". Huangqi-Ezhu (Astragali Radix-Curcumae Rhizoma) is a representative herb pair of herbal medicines that benefit qi and invigorate blood, and studies have shown that this pair and its active ingredients have clear anti-hepatocellular carcinoma effects. In this paper, we have reviewed the literature on the anti-hepatocellular carcinoma mechanism of the Astragali Radix-Curcumae Rhizoma pair and its active ingredients, and reviewed its anti-hepatocellular carcinoma mechanism of action from the aspects of inhibiting proliferation, inducing apoptosis, inhibiting cell metastasis and invasion, inhibiting neoangiogenesis, improving the immune microenvironment, and reversing multidrug resistance, etc., to provide the basis for the clinical use of Astragali Radix-Curcumae Rhizoma pair and the research and development of new Chinese medicine against liver cancer.

国家自然科学基金资助项目（82204656）；山东省高等学校青创人才引育计划（2021505031）；山东中医药大学青年创新团队支持计划（22202105）